Objective: Studies have shown that a sizable percentage of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) is performed outside the instructions for use (IFU). We report our long-term outcomes after EVAR with respect to device-specific IFU. Methods: Computed tomography angiography data from a cohort of 566 patients meeting inclusion criteria who underwent elective EVAR between 2003 and 2014 were examined. Preoperative anatomic measurements for each patient were taken and compared with device-specific IFU. Primary outcomes included all-cause mortality and AAA-related mortality. Secondary outcomes were late-onset rupture, need for reintervention, endoleaks, aneurysm sac enlargement, and intraoperative and perioperative complications. Results: Nine different stent grafts were placed in this set of patients with a mean follow-up of 3.54 6 2.65 years. Most patients (465; 82.2%) were male, and the mean age was 74.8 6 8.70 years. Overall, 176 patients (31.1%) fit all IFU anatomic criteria, and 535 patients (94.5%) fit at least half of IFU criteria. In patients, iliac artery diameter was most commonly outside of IFU (253; 44.7%). A total of 1114 iliac arteries were treated, with 463 (41.6%) treated outside of iliac artery diameter IFU; the majority of these (374; 80.7%) were larger than IFU. Demographics and comorbidities were comparable between the groups within and outside of IFU. AAA-related mortality and all-cause mortality were similar between these two groups, as was late-onset rupture, need for reintervention, rates of endoleak, aneurysm sac enlargement, and major intraoperative and perioperative complications. The sole statistically significant difference in secondary outcomes was increased perioperative blood transfusion needed in those treated outside the IFU, 13.2% vs 6.2% in those treated within IFU (P [ .02); however, this was not associated with decreased access vessel diameter or iliac artery rupture. Conclusions: Despite most EVAR patients being treated outside of IFU, there was no difference in outcomes with respect to all-cause mortality or aneurysm-related mortality. In addition, with the exception of perioperative blood transfusions, there was no association between IFU adherence and late-onset rupture, need for reintervention, rates of endoleak, aneurysm sac enlargement, or most other major complications. (J Vasc Surg 2016;-:1-12.) Abdominal aortic aneurysms (AAAs) are responsible for approximately 13,000 deaths annually in the United States and are the 15th leading cause of death overall and the 10th leading cause of death in men older than 55 years.
Abdominal aortic aneurysms (AAAs) are responsible for approximately 13,000 deaths annually in the United States and are the 15th leading cause of death overall and the 10th leading cause of death in men older than 55 years. 1, 2 Open surgical repair with synthetic graft had been the standard of care for decades to prevent risk of rupture and likely mortality. A new era in vascular surgery was ushered in after the 1991 publication demonstrating successful utilization of a balloon-expandable stent graft that could be delivered endovascularly to treat AAA. 3 This technology was quickly brought to the United States, and the first two endovascular stent grafts gained regulatory approval from the U.S. Food and Drug Administration in 1999. 4 By 2006, endovascular aneurysm repair (EVAR) had overtaken open repair as the most common elective treatment of AAA. 5 In the modern era, there are multiple stent grafts to choose from, each with its own instructions for use (IFU) that detail, among other factors, the recommended anatomic constraints for the particular device to guide selection of patients and to maximize positive outcomes. These anatomic parameters typically include aortic neck diameter and length, aortic neck angulation, and iliac artery diameter and length. A few studies have attempted to look at the relationship between adherence to IFU and EVAR outcomes, but as of yet, there has failed to be a consensus on the matter. [6] [7] [8] [9] [10] [11] In this study, we examined detailed anatomic as well as clinical data in an institutionally maintained database of patients undergoing EVAR to determine the effects of IFU adherence on patient outcomes.
METHODS

This study was implemented at the Mount Sinai Medical
Center and the Icahn School of Medicine at Mount Sinai, an urban tertiary care hospital and medical school located in New York City, New York. The experimental protocol was approved by the Institutional Review Board; patient informed consent was not needed because the data collected were deidentified and analyzed retrospectively.
Patients. Between January 2003 and December 2014, 900 consecutive patients underwent aortic stent graft placement and were included in a prospectively maintained institutional database. Patients with ruptured aneurysms or aortic stent grafts placed for indications other than AAA (eg, pseudoaneurysm, dissection, isolated iliac artery aneurysm) were excluded, as were patients who had prior aneurysm repair. Patients who had planned parallel stent grafts or physician-modified stent grafts placed were similarly excluded. Stent graft selection was the responsibility of and at the sole discretion of the primary operating surgeon. For inclusion in the study, a preoperative computed tomography angiography (CTA) scan with appropriate resolution for three-dimensional reconstruction was required. Whereas there was no strict cutoff for duration of time preoperatively before which a CTA scan would exclude a patient from the study, most patients presented with a CTA scan within 60 days of the procedure. Although postoperative follow-up was individualized to each patient, the general protocol was for follow-up CTA scan within 1 month of the procedure and then at 6 months, 12 months, and yearly thereafter. Patients without an appropriate preoperative CTA scan were excluded from the study.
Imaging. Three-dimensional CTA reconstruction with centerline determination was performed retrospectively using Vitrea (Vital Images, Minnetonka, Minn), and key aneurysm and access vessel morphology (including aortic neck diameter directly and 15 mm below the level of the lowest renal artery, aortic neck length and angulation, maximal aneurysm sac diameter, left and right common and external iliac artery maximal and minimal diameter, and distance from the origin of the lowest renal artery to the aortic bifurcation as well as left and right common iliac length) was measured and recorded by authors blinded to patient outcomes. A strictly defined protocol for measurement was followed to minimize variability between those reading and measuring scans. Patients with CTA scans that could not be reconstructed by Vitrea because of low quality, incomplete scan coverage, or other technical reasons were excluded from the study. In the initial 900 patient database, 222 patients were excluded for this reason.
The prospectively maintained institutional database recorded patient background and demographic data including age, gender, comorbidities, procedure date, device used, and length of stay after EVAR. Comorbid conditions were collected from the electronic medical record. Each patient received a full history and physical examination before surgery, and mention of condition or diagnosis in this or other consultant notes was used in this investigation. Remaining data were gathered from both inpatient electronic medical records and operative reports.
Outcomes. Primary study outcomes were all-cause mortality and aneurysm-related mortality, which was defined as any death within 30 days of the primary EVAR procedure or secondary aneurysm-related intervention or death from aneurysm rupture at any point. Mortality data were gathered from a combination of health system-wide electronic medical records as well as from the Social Security Death Index.
Secondary study outcomes were change in aneurysm sac diameter, intraoperative complications (including deployment-related complications, conversion to open laparotomy, access vessel injury or rupture), perioperative complications (including myocardial infarction, stroke, renal injury, bowel ischemia, access site complication, need for blood transfusion), estimated blood loss (EBL), late-onset AAA rupture, need for aneurysm-related reintervention, late-onset stent graft-related complications (including stent graft migration, kinking, thrombosis, and stent graft fracture), and development of endoleak.
Study outcomes were determined by classifying each patient's stent graft use as occurring either within or Discrete variables were analyzed using a c 2 test, and continuous variables were analyzed using a t-test. Outcomes analysis including all-cause mortality, AAA-related mortality, and time to endoleak, reintervention, rupture, or other complication was performed using Kaplan-Meier analysis with log-rank test. Statistical significance for all tests was set as P < .05.
RESULTS
Patient characteristics. The mean age of the cohort of 566 patients meeting inclusion criteria was 74.8 years at the time of EVAR, with 465 (82.2%) of those patients being male (Table II) . The majority of patients had comorbid hypertension (84.6%), coronary artery disease (66.8%), and hyperlipidemia (73.3%). A bivariate analysis of patient demographic and clinical information showed no difference between the groups within and outside of EVAR IFU (Table II) .
Anatomic and device characteristics. guidelines for anatomic characteristics (because of evolving devices and guidelines) were used (Table II) . In total, 176 (31.1%) patients had stent grafts placed within all devicespecific IFU guidelines. Most of the patients had infrarenal aortic neck measurements of diameter (82.2%), length (82%), and angulation (90.5%) that fell within device IFU (Table III) . The most commonly violated IFU anatomic measurement was iliac artery diameter; 249 patients fell outside of IFU guidelines, equal to either 49% or 44% of the total patient population, respective of the inclusion or exclusion of patients treated with the AneuRx device that lacked iliac artery diameter guidelines. A total of 1114 iliac arteries were treated, with 463 (41.6%) treated outside of iliac artery diameter IFU; the majority of these (374; 80.7%) were larger than IFU. Primary outcomes. There was no difference between groups treated within and outside of device IFU in allcause mortality or AAA-related mortality (Table IV) . Of the total study population, there were 172 all-cause mortalities (30.3%), with 14 (2.5% of total study population, 8.1% of mortalities) of those determined to be AAA related. Of these 14 aneurysm-related mortalities, 3 were perioperative deaths (within 30 days of surgery) and 6 were the result of late-onset aneurysm ruptures (after >30 days). The subset of patients falling within IFU guidelines experienced 55 all-cause mortalities (31.3%) and 5 AAA-related mortalities (2.8%), whereas the group outside IFU experienced 117 all-cause mortalities (30%) and 9 AAA-related mortalities (2.3%). Kaplan-Meier survival analysis of patients within and outside of device IFU demonstrated no difference in freedom from all-cause mortality (P ¼ .64; Fig 1) and aneurysm-related mortality (P ¼ .67; Fig 2) .
Primary outcomes were also analyzed with respect to number of deviations from IFU, from zero deviations (device was placed entirely within IFU) to seven deviations (no anatomic measurement was within IFU guidelines), with right and left iliac artery measurements counted separately. In this analysis, no difference was found in either allcause mortality (P ¼ .99) or aneurysm-related mortality (P ¼ .86) based on number of deviations from IFU ( Supplementary Figs 1 and 2 , online only).
Secondary outcomesdearly.
Early outcomes covering the intraoperative and perioperative periods also showed few major differences between patients treated within and outside of IFU guidelines (Table IV) . There was no difference in the rates of intraoperative complications, device-related complications, perioperative complications, or lengths of stay between the groups treated within and outside of IFU. Adjunctive vascular procedures were performed in 190 patients; 36.9% of patients treated within IFU required an adjunctive vascular procedure compared with 32% of patients treated outside of IFU (65 vs 125 patients; P ¼ .35). The most common adjunctive vascular procedure was femoral endarterectomy with or without patch angioplasty required in 128 patients, followed by internal iliac artery embolization in 42 patients.
Intraoperative EBL was higher in patients treated outside IFU (265.67 vs 224.04 mL) but also fell short of statistical significance (P ¼ .088 using a nonparametric Kruskal-Wallis test due to skewness of 2.53). An increased percentage of patients treated outside of IFU required perioperative blood transfusions (13.2% vs 6.2%), a greater than twofold difference that reached statistical significance (P ¼ .020).
Secondary outcomesdlate. Mean follow-up was 3.54 6 2.65 years for all patients studied with no difference (P ¼ .94) in follow-up between groups treated outside (3.53 years) and within (3.55 years) IFU (Table IV) . Focusing on patients with complete CTA follow-up imaging, 360 patients made it to 1 year postoperatively with imaging, 214 made it to 3 years, and 127 made it to 5 years. No difference was noted in rates of late complications, late-onset stent graft complications, or reintervention between the patient groups treated within and outside of IFU. Postprocedure endoleaks were noted during surveillance in 37.6% of the study population of 566 patients, with the majority of these being type II leaks (29% of study population equating to 77% of all leaks). Type I (8% of study population; 21.1% of leaks) and type III endoleaks (0.3% of study population; 1% of leaks) were the remaining minority of endoleaks found in the population. There were no differences found in groups treated within and outside IFU with respect to all endoleaks, type I endoleaks, type II endoleaks, or type I or III endoleaks. Aneurysm sac diameter was also analyzed on follow-up scans, and sac shrinkage (defined as >5 mm decrease in maximum diameter) was noted in 32.5% of patients, whereas sac enlargement (defined as >5 mm increase in maximum diameter) was found in 11.7% of patients. Once again, there was no significant difference in patients treated within and outside of IFU for either aneurysm sac shrinkage or enlargement. Survival curves comparing patients treated within and outside of IFU guidelines also failed to reach significance with respect to late-onset AAA rupture, reinterventions, and all endoleaks including the type I or III subgroup (Figs 3 to 5 ). Freedom from all-cause related mortality for patients treated within (red line) and outside (blue line) instructions for use (IFU) guidelines (log-rank test, P ¼ .64). All standard errors were <10%.
Infrarenal aortic neck subanalysis. Table V examines primary and select secondary outcomes for patients who had devices placed outside infrarenal aortic neck IFU guidelines. For the group of patients who had devices placed outside the IFU guidelines for infrarenal aortic neck length or infrarenal aortic neck angulation, no difference was found for the primary outcomes of all-cause and AAArelated mortality or for secondary outcomes of reintervention or all and type-specific endoleaks compared with patients who did not violate those particular IFU guidelines. Patients with devices placed outside infrarenal aortic neck diameter IFU guidelines had similar outcomes compared with those within IFU guidelines with respect to all-cause mortality, reintervention, and all as well as type II endoleaks. Of note, no patients who had devices placed in aortic necks too narrow or too wide for IFU guidelines for proximal neck diameter suffered an aneurysm-related mortality (compared with 14 patients who stayed within IFU guidelines for infrarenal neck diameter), a finding that just reached significance (P ¼ .046). In addition, just 4 patients in the group nonadherent to infrarenal neck diameter IFU developed type I endoleaks compared with 45 in the group adherent to such guidelines, a finding that also just reached significance (P ¼ .045).
Length of follow-up analysis. Tables VI and VII look at primary outcomes and specific secondary outcomes for patients within and outside of IFU with selected follow-up intervals. All-cause mortality and AAA-related mortality in patients within and outside of IFU demonstrated no difference at follow-up lengths of 1 month or yearly thereafter up to the 9 years of follow-up studied. There was also no difference in secondary outcomes of rates of all endoleaks or rates of type I or type III endoleaks during the same time intervals with the exception of an isolated difference in type I endoleak rates at the post-3-year interval. Eight of 81 patients operated on within IFU (11.4%) developed a type I endoleak vs 6 of 194 patients (4.1%) outside IFU, a difference (P ¼ .03) not seen in any time period following. This analysis included only patients with complete follow-up CTA imaging at the designated time intervals.
There was an extended period, however, during which differences were seen in rates of reintervention. This difference started at the first year (21.2% reintervention rate after the first year within IFU vs 12% outside of IFU; P ¼ .015) and persisted until the seventh year (28.6% reintervention rate within IFU vs 2.3% outside of IFU; P ¼ .015), with the exception of the fifth year. The later time intervals were notable for lower sample sizes, with the aforementioned analysis at 7 years including only 15% (85/566) of the total population owing to the length of follow-up.
DISCUSSION
The prevalence of EVAR to treat AAA has been steadily increasing, validated by a number of randomized controlled studies showing decreased perioperative mortality and noninferior long-term mortality vs traditional open surgery in addition to obvious benefits including decreased length of stay.
12-14 IFU guidelines for these endovascular stent graft devices exist, in part, to guide selection of patients to maximize outcomes. Along with the large amounts of preoperative patient clinical information the operator must consider, the AAA patient's vascular anatomy is examined to determine suitability for as well as size of the EVAR device to be used. The few studies that have examined EVAR outcomes based on IFU adherence have returned conflicting results.
Our study hoped to shed light on this matter by examining the results for a decade from a single, high-volume institution with experience using multiple devices. Because Our observation of fewer patients being treated within IFU compared with earlier studies likely reflects the realities of patient presentation at an institution referred a large percentage of patients with more challenging anatomy. In addition, a long-standing investigational device exemption meant it was more likely that many patients had devices placed outside IFU, especially earlier in the studied period. This investigational device exemption granted early access to devices, before determination of IFU anatomic guidelines, and it was likely that this influenced selection of patients to some extent. Finally, as a result of the strict imaging criteria for inclusion, patients with less challenging anatomy may have been excluded if their preoperative workup did not have the necessary imaging coverage and detail. An interesting subanalysis of the population of patients in this study revealed that there was no statistically significant difference in regard to the effect of gender on IFU adherence. Given recent studies showing increased periprocedural complications and confirming narrower preoperative vascular anatomy in female patients undergoing EVAR, it was surprising that this did not correspond to a decrease in IFU adherence in women relative to men. 15 Despite the decreased IFU adherence found in our study population, primary outcomes of all-cause mortality and AAA-related mortality did not differ compared with patients treated within IFU guidelines. This echoes more recent studies, including those of Walker et al (489-patient study from 2015) and Lee et al (218-patient study from 2013), showing similar mortality outcomes. It was interesting to note that as the number of deviations from IFU increased, all-cause mortality and aneurysm-related mortality did not show worse outcomes. Earlier studies, such as the 2008 565-patient study by Abbruzzese et al, found higher AAA-related mortality in the long term with violation of IFU guidelines. The most cited study, Schanzer et al's examination of 10,228 patients published in 2011, showed that deviation from IFU guidelines resulted in increased aneurysm sac diameter over time. This study, although clearly pivotal in nature, suffered from the acknowledged drawbacks inherent in a database study that lacked patient information including device placement, patient demographics, morbidity, mortality, and other intraoperative, perioperative, and postoperative outcomes. A metric that could be measured, increased aneurysm sac diameter, was used as a surrogate for possible poorer outcomes because of concern for long-term rupture; however, the correlation of increased aneurysm sac size and increased risk of rupture has not been as validated in patients after EVAR as in those who have not been operated on. Indeed, not only did our study show no increased risk of rupture or AAA-related mortality for patients treated outside of IFU, but we also found no difference in aneurysm sac diameter change (either increase or decrease) correlating with IFU adherence.
In addition to the lack of any correlation of IFU adherence to aneurysm sac diameter change, all but one of the numerous secondary outcomes measured in this study also demonstrated no difference between these patients treated within and outside of IFU, again seeming to agree with later studies, including those of Lee et al and Walker et al. There was a difference found, however, in the need for perioperative blood transfusion, occurring more than twice as frequently (13.2% vs 6.2%; P ¼ .02) in patients undergoing EVAR outside IFU. Notably, although EBL was also increased in patients undergoing EVAR outside IFU vs those within IFU, it came close to but did not achieve statistical significance (P ¼ .065). Other explanations, such as intraoperative complications or perioperative access site complications, did not demonstrate any difference between these two groups.
Notwithstanding the low IFU adherence seen in this study, most patients were treated within IFU for infrarenal aortic neck anatomy, with iliac artery diameter the most likely reason for a patient to be outside IFU. Infrarenal neck dimensions, specifically infrarenal aortic neck diameter and angulation, have been implicated in suboptimal outcomes in a number of studies. [16] [17] [18] These findings are the rationale for our subanalysis of the effect of nonadherence to individual infrarenal aortic neck IFU on primary as well as selected secondary outcomes. In regard to adherence to proximal neck length or angulation, in contrast to some earlier studies, no differences were found with respect to all-cause mortality, AAA-related mortality, reinterventions, or endoleaks. In examining the proximal neck diameter, however, there was a statistically significant difference found in AAA-related mortality as well as in type I and type III endoleaks noted between groups treated within and outside of IFU for this anatomic parameter. Counterintuitively, better outcomes were noted with violation of this particular IFU guideline, with no AAA-related mortalities and only 4 type I or type III endoleaks seen in this group of 101. Although noteworthy, it would be illogical to conclude that such violations actually improve patient outcomes, especially considering the statistical significance (P ¼ .046 and .032, respectively). It could be also be possible that differences between these two groups in device type, suprarenal fixation, or oversizing of the main body device are responsible for the results that are seen, the analysis of which has become the next focus of our investigations into outcomes of EVAR. It is also possible that the constraints of clinical trials performed limited the off-label utilization of devices used to improve outcomes. As more patients in this subgroup are studied and existing patients are followed up for a longer amount of time, it would be logical that these statistically significant differences will fall away.
Similarly interesting but counterintuitive results are noted in the time interval analysis of outcomes. Whereas primary outcomes and rates of endoleaks demonstrated no difference at any of the selected time intervals, rates of reintervention were greater in patients treated within IFU from postoperative year 1 through year 7 with the exception of year 5. There was no association between these findings and rates of endoleak or any other endograftrelated complication, so a definitive explanation for these findings is not evident. Again, it will be interesting to see if these findings hold up as length of follow-up in this cohort increases.
Our study has several limitations that can be acknowledged. The nature of a retrospective review of a prospectively maintained database of a nonrandomized patient population means there will be selection biases and other biases inherent when individual surgeons attempt to optimize outcomes for each unique patient. Individual surgeons not only selected patients for EVAR but also drove device selection as well. This study did not look at ruptures and excluded patients without detailed preoperative CTA imaging. This might exclude some patients whose anatomy was considered straightforward enough to not merit a detailed scan or other patients whose main reference imaging was invasive aortography and angiography. Whereas the Vitrea software is a good guide for detailed straightline anatomic measurements, it is also subject to human error, especially with many authors and surgeons contributing to the collection of these measurements. A strictly defined protocol for measurement was created and followed, however, to minimize this source of error. Finally, although the follow-up period was respectable in comparison to similar studies (mean, 3.54 years), longer follow-up may reveal differences that have not had a chance to present themselves in the period studied. It is also possible that given the concentration of different medical institutions in the surrounding area, some patients may have had follow-up and reintervention outside our institution of which we have no records.
CONCLUSIONS
Despite the majority of EVAR patients studied during a 10-year period being treated outside of device-specific IFU based on detailed anatomic data, there was no effect of this difference on primary outcomes of either all-cause mortality of AAA-related mortality. There was also no association with IFU adherence on most secondary outcomes, including intraoperative complications, length of stay, late-onset complications, late-onset AAA rupture, need for reintervention, all endoleaks, and change in aneurysm sac diameter. The sole statistically significant difference found was an increased rate of blood transfusions in patients treated outside IFU, a difference not associated with increased EBL or access vessel complications.
